Analysts See $-0.25 EPS for Endocyte, Inc. (ECYT); Sandridge Mississippian Trust I (SDT) Sentiment Is 0.55

July 17, 2017 - By Migdalia James

SandRidge Mississippian Trust I is a statutory trust formed by and among SandRidge Energy, Inc. , The Bank of New York Mellon Trust Company, N.A., and The Corporation Trust Company. The company has market cap of $41.45 million. Sandridge offers various services to the Company, such as the operation of its development wells; remittance of net proceeds from the sale of associated production to the Company; administrative services, such as accounting, tax preparation, bookkeeping and informational services performed on behalf of the Company, and derivative agreement services related to production. It has a 5.1 P/E ratio. The Firm holds Royalty Interests in specified oil and natural gas properties located in the Mississippian formation in Alfalfa, Garfield, Grant and Woods counties in Oklahoma.

Analysts expect Endocyte, Inc. (NASDAQ:ECYT) to report $-0.25 EPS on August, 3.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.25 EPS. After having $-0.27 EPS previously, Endocyte, Inc.’s analysts see -7.41% EPS growth. About 396,481 shares traded. Endocyte, Inc. (NASDAQ:ECYT) has declined 24.78% since July 17, 2016 and is downtrending. It has underperformed by 41.48% the S&P500.

Among 4 analysts covering Endocyte (NASDAQ:ECYT), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Endocyte had 6 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Hold” rating by Cowen & Co on Friday, June 2. The stock has “Outperform” rating by Credit Suisse on Thursday, January 21. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, August 5. The firm has “Outperform” rating given on Wednesday, November 4 by RBC Capital Markets. The rating was downgraded by Cowen & Co to “Market Perform” on Monday, June 5. The rating was downgraded by Wedbush on Monday, June 5 to “Neutral”.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.49, from 0.89 in 2016Q3. It improved, as 7 investors sold Endocyte, Inc. shares while 22 reduced holdings. 13 funds opened positions while 27 raised stakes. 14.71 million shares or 4.95% less from 15.48 million shares in 2016Q3 were reported. Nationwide Fund Advsr has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). New York-based D E Shaw Inc has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Susquehanna Gru Llp owns 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 116,057 shares. Bessemer Group stated it has 15,850 shares or 0% of all its holdings. Cortland Assoc Incorporated Mo holds 10,000 shares. North Carolina-based Sterling Mgmt Limited Liability has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Rmb Management Ltd Liability has invested 0.03% in Endocyte, Inc. (NASDAQ:ECYT). Rhumbline Advisers holds 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 42,706 shares. Hilltop holds 0.01% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 10,720 shares. Hall Laurie J Trustee reported 270 shares. Financial Bank Of America Corp De reported 10,303 shares. The Indiana-based 1St Source Bancorp has invested 0.01% in Endocyte, Inc. (NASDAQ:ECYT). Art Advsrs Ltd Co reported 25,100 shares. Two Sigma Securities Limited Liability Co accumulated 26,758 shares or 0.02% of the stock. Meeder Asset Management holds 0% in Endocyte, Inc. (NASDAQ:ECYT) or 5,657 shares.

Endocyte Inc. is a biopharmaceutical company. The company has market cap of $65.23 million. The Firm is engaged in developing therapies for the treatment of cancer and inflammatory diseases. It currently has negative earnings. The Firm uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: